SOPHIA ANTIPOLIS, France, April 24, 2015 (GLOBE NEWSWIRE) -- Nicox S.A. (Euronext Paris: FR0000074130, COX), has convened an ordinary and extraordinary shareholder meeting on Wednesday June 3, 2015 at 2:00 pm CET at the Hotel Mercure - rue Albert Caquot - 06560 Sophia Antipolis - France.
The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French Code de commerce, including a proxy voting form, will be sent to shareholders upon written request. These documents will also be made available to shareholders at the headquarters and on the website of the Company ( www.nicox.com ) by May 13, 2015.
Shareholders may vote by proxy, by internet or by attending the shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, will be posted on Nicox's website by May 13, 2015. Shareholders may also contact the Company's Investor Relations team at communications@nicox.com for any question on the voting process.
In the event the quorum is not reached on the first call, Nicox will convene a shareholder meeting on a second call on Wednesday June 17, 2015 at 2:00 pm CET at the Hotel Mercure - rue Albert Caquot - 06560 Sophia Antipolis - France.
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, we are building a diversified portfolio of ophthalmic products that can help people to enhance their sight.
Nicox's advanced pipeline features two pre-NDA candidates (Vesneo(TM) for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite ® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe's five largest markets complemented by an expanding international network of distributors.
Nicox is headquartered in France and has more than 120 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
For more information on Nicox, its commercial products or pipeline, please visit www.nicox.com .
| Analyst coverage | ||||
| Bryan, Garnier & Co | Hugo Solvet | Paris | ||
| Stifel | Max Herrmann | London | ||
| Invest Securities | Martial Descoutures | Paris |
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 4 th chapter of the ' Document de référence, rapport financier annuel et rapport de gestion 2014 ' filed with the French Autorité des Marchés Financiers (AMF) on April 10, 2015, which is available on Nicox's website ( www.nicox.com ).
| Contacts | |
| Nicox | Gavin Spencer | Executive Vice President Corporate Development |
| Caroline Courme | Communication Manager | |
| Tel +33 (0)4 97 24 53 43 | communications@nicox.com |
Shareholder meetings http://hugin.info/143509/R/1914016/683794.pdf
HUG#1914016
